Comparison of birth control methods: Difference between revisions

Content deleted Content added
citation added
consistent citation formatting
Line 1:
{{Short description|none}}
{{Use American English|date=February 2023}}
{{cs1 config|name-list-style=vanc}}
[[File:Effectivenessofcontraceptives.png|thumb|440px|Effectiveness of contraceptive methods with respect to birth control. Only condoms are useful to prevent [[sexually transmitted infections]].]]
 
Line 58 ⟶ 59:
 
==User dependence==
Different methods require different levels of diligence by users. Methods with little or nothing to do or remember, or that require a clinic visit less than once per year are said to be ''non-user dependent'', ''forgettable,'' or ''top-tier'' methods.<ref name="Hatcher20th">{{Cite book |title=Contraceptive Technology |publisher=Ardent Media |year=2011 |isbn=978-1-59708-004-0 |editor-last veditors = Hatcher |editor-first=RobertRA, A.Trussell J, Nelson AL |edition=20th |___location=New York |editor-last2=Trussell |editor-first2=James |editor-last3=Nelson |editor-first3=Anita L. |name-list-style=vanc}}{{page needed|date=June 2012}}</ref> Intrauterine methods, implants, and sterilization fall into this category.<ref name="Hatcher20th" /> For methods that are not user dependent, the actual and perfect-use failure rates are very similar.
 
Many hormonal methods of birth control, and LAM require a moderate level of thoughtfulness. For many hormonal methods, clinic visits must be made every three months to a year to renew the prescription. The pill must be taken every day, the patch must be reapplied weekly, or the ring must be replaced monthly. Injections are required every 12 weeks. The rules for LAM must be followed every day. Both LAM and hormonal methods provide a reduced level of protection against pregnancy if they are occasionally used incorrectly (rarely going longer than 4–6 hours between breastfeeds, a late pill or injection, or forgetting to replace a patch or ring on time). The actual failure rates for LAM and hormonal methods are somewhat higher than the perfect-use failure rates.{{citation needed|date=September 2023}}
 
Higher levels of user commitment are required for other methods.<ref>{{Cite report |url=http://www.fhi.org/NR/rdonlyres/eoabicg5w53xarcybsiefba5ruvr6r2dnkws7vj2hr3ndzv225gkvw2oxtkdlxzcl5yr3q3iok4kid/Mera08091.pdf |title=Helping women understand contraceptive effectiveness |last vauthors = Shears |first=KathleenKH, Henry |last2=Aradhya |first2=Kerry WrightKW |date=July 2008 |publisher=Family Health International |name-list-style=vanc}}</ref> Barrier methods, coitus interruptus, and spermicides must be used at every act of intercourse. Fertility awareness-based methods may require daily tracking of the menstrual cycle. The actual failure rates for these methods may be much higher than the perfect-use failure rates.<ref>{{Cite book |last vauthors = Trussell |first=JamesJ |url=https://archive.org/details/contraceptivetec00hatc |title=Contraceptive Technology |publisher=Ardent Media |year=2007 |isbn=978-0-9664902-0-6 |editor-last veditors = Hatcher |editor-first=RobertRA, A.Trussell J, Nelson AL |edition=19th |___location=New York |chapter=Contraceptive Efficacy |editor-last2=Trussell |editor-first2=James |editor-last3=Nelson |editor-first3=Anita L. |chapter-url=http://www.contraceptivetechnology.org/table.html |url-access=registration |name-list-style=vanc}}{{page needed|date=June 2012}}</ref><!-- NOTE: This reference is to the same work as is referred to in the table, but the table has a separate reference list, so do not remove the body of this reference -->
 
==Side effects==
Line 71 ⟶ 72:
Barrier methods have a risk of allergic reactions. Users sensitive to latex may use barriers made of less allergenic materials - polyurethane condoms, or silicone diaphragms, for example. Barrier methods are also often combined with spermicides, which have possible side effects of genital irritation, vaginal infection, and urinary tract infection.{{citation needed|date=April 2022}}
 
Sterilization procedures are generally considered to have a low risk of side effects, though some persons and organizations disagree.<ref>{{Cite web |last vauthors = Bloomquist |first=Michele |name-list-style=vancM |date=May 2000 |title=Getting Your Tubes Tied: Is this common procedure causing uncommon problems? |url=http://www.medicinenet.com/script/main/art.asp?articlekey=51216 |access-date=2006-09-25 |website=MedicineNet.com |publisher=WebMD}}</ref><ref>{{Cite web |last=Hauber |firstvauthors =Kevin C.Hauber |name-list-style=vancKC |title=If It Works, Don't Fix It! |url=http://www.dontfixit.org/ |access-date=2006-09-25}}{{MEDRS|date=September 2012}}</ref> Female sterilization is a more significant operation than vasectomy, and has greater risks; in industrialized nations, mortality is 4 per 100,000 tubal ligations, versus 0.1 per 100,000 vasectomies.<ref>{{Cite journal |vauthors=Awsare NS, Krishnan J, Boustead GB, Hanbury DC, McNicholas TA |date=November 2005 |title=Complications of vasectomy |journal=Annals of the Royal College of Surgeons of England |volume=87 |issue=6 |pages=406–10 |doi=10.1308/003588405X71054 |pmc=1964127 |pmid=16263006}}</ref>
 
After IUD insertion, users may experience irregular periods in the first 3–6 months with Mirena, and sometimes heavier periods and worse menstrual cramps with ParaGard. However, continuation rates are much higher with IUDs compared to non-long-acting methods.<ref>{{Cite journal |last=Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group |date=November 2017 |title=Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices |url=https://www.ncbi.nlm.nih.gov/pubmed/29064972 |journal=Obstetrics and Gynecology |volume=130 |issue=5 |pages=e251–e269 |doi=10.1097/AOG.0000000000002400 |issn=1873-233X |pmid=29064972 |s2cid=35477591}}</ref> A positive characteristic of IUDs is that fertility and the ability to become pregnant returns quickly once the IUD is removed.<ref>{{Cite web |title=Planned Parenthood IUD Birth Control - Mirena IUD - ParaGard IUD |url=http://www.plannedparenthood.org/health-topics/birth-control/iud-4245.htm |access-date=2012-02-26}}</ref>
 
Because of their systemic nature, hormonal methods have the largest number of possible side effects.<ref>{{Cite web |last=Staff |first=Healthwise. |title=Advantages and Disadvantages of Hormonal Birth Control |url=http://healthlinksbc.org/kb/content/frame/tw9513.html |access-date=2010-07-06}}</ref> Combined hormonal contraceptives contain estrogen and progestin hormones.<ref name="teal-2021">{{Citecite journal |last vauthors = Teal |first=StephanieS, |last2=Edelman |first2=AlisonA |date=2021-12-28 |title = Contraception Selection, Effectiveness, and Adverse Effects: A Review |url=https://jamanetwork.com/journals/jama/fullarticle/2787541 |journal=JAMA |language=en Jama | volume = 326 | issue = 24 | pages = 2507–2518 | date = December 2021 | pmid = 34962522 | doi = 10.1001/jama.2021.21392 |issn=0098-7484 |pmids2cid =34962522 |s2cid=245557522 | doi-access = free }}</ref> They can come in formulations such as pills, vaginal rings, and transdermal patches.<ref name="teal-2021" /> Most people who use combined hormonal contraception experience breakthrough bleeding within the first 3 months.<ref name="teal-2021" /> Other common side effects include headaches, breast tenderness, and changes in mood.<ref name="barr-2020">{{Citecite journal |last=Barr |firstvauthors =Nancy Grossman |date=DecemberBarr 15,N 2020| |title = Managing Adverseadverse Effectseffects of Hormonalhormonal Contraceptivescontraceptives |url=https://www.aafp.org/afp/2010/1215/afp20101215p1499.pdf |journal = American Family Physician | volume = 82 | issue = 12 | pages = 1499–1506 | date = December 2010 | pmid = 21166370 |via=American Academyurl of= Familyhttps://www.aafp.org/afp/2010/1215/afp20101215p1499.pdf Physicians}}</ref> Side effects from hormonal contraceptives typically disappear over time (3-5 months) with consistent use.<ref name="barr-2020" /> Less common effects of combined hormonal contraceptives include increasing the risk of deep vein thrombosis to 2-10 per 10,000 women per year and venous thrombotic events (see [[venous thrombosis]]) to 7-10 per 10,000 women per year.<ref name="teal-2021" />
 
Hormonal contraceptives can come in multiple forms including injectables. Depot medroxyprogesterone acetate (DMPA), a progestin-only injectable, has been found to cause [[amenorrhea]] (cessation of menstruation); however, the irregular bleeding pattern returns to normal over time.<ref name="teal-2021" /><ref name="barr-2020" /> DMPA has also been associated with weight gain.<ref name="barr-2020" /> Other side effects more commonly associated with progestin-only products include [[acne]] and [[hirsutism]].<ref name="barr-2020" /> Compared to combined hormonal contraceptives, progestin-only contraceptives typically produce a more regular bleeding pattern.<ref name="teal-2021" />
Line 85 ⟶ 86:
[[condom|Male]] and [[female condom]]s provide significant protection against [[sexually transmitted infection]]s (STIs) when used consistently and correctly. They also provide some protection against [[cervical cancer]].<ref>{{Cite journal |vauthors=Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA |date=June 2006 |title=Condom use and the risk of genital human papillomavirus infection in young women |journal=The New England Journal of Medicine |volume=354 |issue=25 |pages=2645–54 |doi=10.1056/NEJMoa053284 |pmid=16790697 |doi-access=free}}</ref><ref>{{Cite journal |vauthors=Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, Westenend PJ, Meijer CJ |date=December 2003 |title=Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial |journal=International Journal of Cancer |volume=107 |issue=5 |pages=811–6 |doi=10.1002/ijc.11474 |pmid=14566832 |doi-access=free}}</ref> Condoms are often recommended as an adjunct to more effective birth control methods (such as [[IUD]]) in situations where STI protection is also desired.<ref>{{Cite journal |vauthors=Cates W, Steiner MJ |date=March 2002 |title=Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach? |journal=Sexually Transmitted Diseases |volume=29 |issue=3 |pages=168–74 |doi=10.1097/00007435-200203000-00007 |pmid=11875378 |s2cid=42792667 |doi-access=free}}</ref>
 
Other barrier methods, such as [[Diaphragm (contraceptive)|diaphragms]] may provide limited protection against infections in the upper genital tract. Other methods provide little or no protection against sexually transmitted infections. <ref>{{Citecite journal |last vauthors = Deese |first=JenniferJ, |last2=Pradhan |first2=SubarnaS, |last3=Goetz |first3=HannahH, |last4=Morrison |first4=CharlesC |date=2018-11-12 |title = Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives |url language =https://www.dovepress.com/contraceptive-use-and-the-risk-of-sexually-transmitted-infection-syste-peer-reviewed-fulltext-article-OAJC English | journal = Open Access Journal of Contraception |language=English |volume = 9 | pages = 91–112 | date = 2018-11-12 | pmid = 30519127 | pmc = 6239113 | doi = 10.2147/OAJC.S135439 |pmc=PMC6239113 |pmid=30519127}}</ref>
 
==Effectiveness==
Line 96 ⟶ 97:
Not using contraceptives is the most expensive option. While in that case there are no method related costs, it has the highest failure rate, and thus the highest failure related costs. Even if one only considers medical costs relating to preconception care and birth, any method of contraception saves money compared to using no method.{{Citation needed|date=September 2023}}
 
The most effective and the most cost-effective methods are long-acting methods. Unfortunately these methods often have significant up-front costs, and requiring the user to pay a portion of these costs prevents some from using more effective methods.<ref>{{Citecite journal | vauthors = Cleland K, Peipert JF, Westhoff C, Spear S, Trussell J |date=May 2011 |title = Family planning as a cost-saving preventive health service | journal = The New England Journal of Medicine | volume = 364 | issue = 18 | pages = e37 | date = May 2011 | pmid = 21506736 | doi = 10.1056/NEJMp1104373 |pmid=21506736}}</ref> Contraception saves money for the public health system and insurers.<ref>{{Citecite journal |last vauthors =Jennifer J. Frost |last2=Lawrence B.JJ, Finer |last3=AthenaLB, Tapales A |date=2008 |title = The Impactimpact of Publiclypublicly Fundedfunded Familyfamily Planningplanning Clinicclinic Servicesservices on Unintendedunintended Pregnanciespregnancies and Governmentgovernment Costcost Savingssavings |url=http://muse.jhu.edu/content/crossref/journals/journal_of_health_care_for_the_poor_and_underserved/v019/19.3.frost.html |journal = Journal of Health Care for the Poor and Underserved |language=en |volume = 19 | issue = 3 | pages = 778–796 | date = August 2008 | pmid = 18677070 | doi = 10.1353/hpu.0.0060 |issn=1548-6869 |pmid=18677070 |s2cid = 14727184 }}</ref>{{Relevance inline|date=September 2023}}
 
===Effectiveness calculation===
Line 163 ⟶ 164:
| Tube tying, female sterilization || style=background:#e0ffff | {{sort|000.50|0.5}} <br />(1 in 200) || style=background:#e0ffff | {{sort|000.50|0.5}} <br />(1 in 200) || Sterilization || Surgical procedure ||style=background:#e0ffff| {{sort | 98.000 | Once}}
|-
| Bilateral [[salpingectomy]]<ref>{{Citecite journal |last vauthors = Castellano |first=TaraT, |last2=Zerden |first2=MatthewM, |last3=Marsh |first3=LauraL, |last4=Boggess |first4=KimK |date=November 2017title |title= Risks and Benefits of Salpingectomy at the Time of Sterilization | journal = Obstetrical & Gynecological Survey | volume = 72 | issue = 11 | pages = 663–668 | date = November 2017 | pmid = 29164264 | doi = 10.1097/OGX.0000000000000503 |pmid=29164264}}</ref>
| Tube removal, "bisalp" || style=background:#e0ffff | {{sort|000.75|0.75}} (1 in 133) after 10 years<ref group="note">No data for 1 year failure rates</ref> || style=background:#e0ffff | {{sort|000.75|0.75}} after 10 years || Sterilization || Surgical procedure || style=background:#e0ffff | {{sort| 98.000 | Once}}
|-
Line 172 ⟶ 173:
| Sensiplan by Arbeitsgruppe NFP ([[Malteser International|Malteser Germany]] gGmbh) || style=background:#e0ffe0 | {{sort|001.68|1.68}} <br />(1 of 60) || style=background:#e0ffff | {{sort|000.43|0.43}}<br /> (1 in 233) || Behavioral || Teaching sessions, observation, charting and evaluating a combination of fertility symptoms|| {{sort | 00.006 | Three teaching sessions + daily application}}
|-
| [[Lactational amenorrhea method|LAM]] for 6 months only; not applicable if menstruation resumes<ref>{{Cite book |last vauthors = Trussell |first=JamesJ |url=https://archive.org/details/contraceptivetec00hatc/page/773 |title=Contraceptive Technology |publisher=Ardent Media |year=2007 |isbn=978-0-9664902-0-6 |editor-last veditors = Hatcher |editor-first=RobertRA, Trussell J, Nelson AL A. |edition=19th |___location=New York |pages=[https://archive.org/details/contraceptivetec00hatc/page/773 773–845] |chapter=Contraceptive Efficacy |editor-last2=Trussell |editor-first2=James |editor-last3=Nelson |editor-first3=Anita L. |chapter-url=http://www.contraceptivetechnology.org/table.html |url-access=registration |name-list-style=vanc}}</ref><ref group="note">The pregnancy rate applies until the user reaches six months postpartum, or until menstruation resumes, whichever comes first. If menstruation occurs earlier than six months postpartum, the method is no longer effective. For users for whom menstruation does not occur within the six months: after six months postpartum, the method becomes less effective.</ref>
| Ecological breastfeeding || style="background:#e0ffe0" | {{sort|002.00|2}} <br />(1 in 50) || style=background:#e0ffff | {{sort|000.50|0.5}} <br />(1 in 200) || Behavioral || Breastfeeding || {{sort | 00.004 | Every few hours}}
|-
Line 178 ⟶ 179:
| [[Lea's Shield]] || style=background:#e0ffe0 | {{sort|005.00|5}} <br />(1 in 20) || style=background:#dcdcdc | {{sort|100.00|no data}} || Barrier & spermicide || Vaginal insertion || {{sort | 00.030 | Every act of intercourse}}
|-
| [[Medroxyprogesterone acetate|MPA]] shot<ref name="ReferenceA">{{cite web | title = Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States | url = http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/Contraceptive-Failure-Rates.pdf {{Webarchive| archive-url = https://web.archive.org/web/20220504005547/http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/Contraceptive-Failure-Rates.pdf | archive-date =2022-05-04 }}4 {{BareMay URL2022 PDF|date=March 2022}}</ref>
| [[Depo Provera]], the shot || style="background:#ffffc0" | {{sort|004.00|4}} <br />(1 in 25) || style=background:#e0ffff | {{sort|000.20|0.2}}<br />(1 in 500) || Progestogen || Injection || {{sort | 00.300 | 12 weeks}}
|-
Line 199 ⟶ 200:
| POP, minipill || style=background:#ffffc0 | {{sort|009.00|9}}<ref name="contraceptivetechnology.org" /><br />(1 in 11) || style=background:#e0ffff | {{sort|000.30|0.3}}<br />(1 in 333) || Progestogen + placebo<ref name="placebo" /> || Oral medication || {{sort | 00.010 | Daily}}
|-
| [[Ormeloxifene]]<ref>{{Cite book |title=Pharmacology for Health in Asia : Proceedings of Asian Congress of Pharmacology, 15–19 January 1985, New Delhi, India |vauthors=Puri V |publisher=Allied Publishers |year=1988 |editor-last veditors =Dhwan B.Dhwan N.BN |___location=Ahmedabad |chapter=Results of multicentric trial of Centchroman |display-editors=etal}}<br /> {{Cite book |title=Hormone Antagonists for Fertility Regulation |vauthors=Nityanand S |publisher=Indian Society for the Study of Reproduction and Fertility |year=1990 |veditors=Puri CP, Van Look PF |___location=Bombay |chapter=Clinical evaluation of Centchroman: a new oral contraceptive}}</ref>
| Saheli, Centron || style=background:#ffffc0 | {{sort|009.00|9}} <br /> (1 in 11)|| style=background:#e0ffe0 | {{sort|002.00|2}}<br />(1 in 50) || [[Selective estrogen receptor modulator|SERM]] || Oral medication || {{sort | 00.070 | Weekly}}
|-